Home › Research › Treatments
Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review
Kalampokini S, Keramidiotis I, Frontistis A, Zuchi F, Michmizos D, Papaliagkas V, Koutsouraki E.. Journal of clinical medicine, 2026-09-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This umbrella review included 11 systematic reviews and/or meta-analyses. Patients treated with lecanemab or donanemab showed statistically significant changes on cognitive scales such as the Clinical Dementia Rating-Sum of Boxes (CDR-SB) (mean effect estimate -0.485, SD = 0.152, -0.70 to -0.34) and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), but most were below or around clinically meaningful thresholds. Lecanemab and donanemab showed a statistically significant decrease in amyloid PET outcomes, including centiloids or the standardized uptake value ratio. Both antibodies were linked to ARIA, including amyloid-related imaging abnormalities-edema (ARIA-E OR 8.32-12.26) and amyloid-related imaging abnormalities-hemorrhage (ARIA-H OR 2-5.77), especially in ApoEε4 carriers. Lecanemab and donanemab are biologically active drugs for the treatment of early AD, with cognitive benefits below or around the clinically meaningful threshold. They are, however, associated with increased ARIA risk. Their administration depends upon careful patient selection, shared decision-making, and clear communication regarding expectations.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kalampokini, S., Keramidiotis, I., Frontistis, A., Zuchi, F., Michmizos, D., Papaliagkas, V., et al. (2026). Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review. Journal of clinical medicine. https://doi.org/10.3390/jcm15176782
Vancouver
Kalampokini S, Keramidiotis I, Frontistis A, Zuchi F, Michmizos D, Papaliagkas V, et al. Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review. Journal of clinical medicine. 2026. doi:10.3390/jcm15176782. PMID: 42739787.
BibTeX
@article{kalampokini2026-42739787,
author = {Kalampokini, S. and Keramidiotis, I. and Frontistis, A. and Zuchi, F. and Michmizos, D. and Papaliagkas, V. and Koutsouraki, E.},
title = {{Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review}},
journal = {Journal of clinical medicine},
year = {2026},
doi = {10.3390/jcm15176782},
pmid = {42739787},
url = {https://doi.org/10.3390/jcm15176782}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- This umbrella review included 11 systematic reviews and/or meta-analyses.
- Patients treated with lecanemab or donanemab showed statistically significant changes on cognitive scales such as the Clinical Dementia Rating-Sum of Boxes (CDR-SB) (mean effect estimate -0.485, SD = 0.152, -0.70 to -0.34) and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), but most were below or around clinically meaningful thresholds.
- Lecanemab and donanemab showed a statistically significant decrease in amyloid PET outcomes, including centiloids or the standardized uptake value ratio.
- Both antibodies were linked to ARIA, including amyloid-related imaging abnormalities-edema (ARIA-E OR 8.32-12.26) and amyloid-related imaging abnormalities-hemorrhage (ARIA-H OR 2-5.77), especially in ApoEε4 carriers.
- Lecanemab and donanemab are biologically active drugs for the treatment of early AD, with cognitive benefits below or around the clinically meaningful threshold.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designmeta-analysis
- Effect sizeOR 8.32-12.26
- Evidence strengthHigh
How this study scored 79/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for sample size and studied in people because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 46 of the 58 points we could judge it on, which is 79 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of clinical medicine) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42739787) |
| Free to read | 2 / 2 | Free to read |
| Points | 46 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 46 of the 58 points we could judge it on is 79 out of 100. |
| Total | 79 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “umbrella”
4 studies in the library carry the topic tag “umbrella”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 4 tagged studies.